AZ to appeal NICE rejection for lung cancer drug
The committee didn’t OK the drug as the cost effectiveness estimates were above what NICE normally considers to be an acceptable use of NHS resources.
Read More
Tag: End of Life status
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
